These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
23. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients. Provinciali M; Di Stefano G; Stronati S; Fabris N Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903 [TBL] [Abstract][Full Text] [Related]
24. Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells. Fujiwara T; Grimm EA Cancer Res; 1992 Sep; 52(18):4954-9. PubMed ID: 1387585 [TBL] [Abstract][Full Text] [Related]
25. Interleukin-4 differentially regulates interleukin-2-mediated and CD2-mediated induction of human lymphokine-activated killer effectors. Robinet E; Kamoun M; Farace F; Chouaib S Eur J Immunol; 1992 Nov; 22(11):2861-5. PubMed ID: 1358624 [TBL] [Abstract][Full Text] [Related]
26. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2. Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140 [TBL] [Abstract][Full Text] [Related]
27. Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors. Maghazachi AA Immunology; 1990 Aug; 70(4):465-72. PubMed ID: 2118478 [TBL] [Abstract][Full Text] [Related]
28. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha. López-Rodríguez JL; Cordero OJ; Sarandeses C; Viñuela J; Nogueira M Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426 [TBL] [Abstract][Full Text] [Related]
29. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro. Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536 [TBL] [Abstract][Full Text] [Related]
30. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines. Parhar RS; Ernst P; Sheth KV; al-Sedairy ST Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260 [TBL] [Abstract][Full Text] [Related]
31. Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes. Brooks B; Parry H; Lawry J; Rees R Immunology; 1992 Feb; 75(2):343-8. PubMed ID: 1551696 [TBL] [Abstract][Full Text] [Related]
32. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity. Reiter Z Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture. Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989 [TBL] [Abstract][Full Text] [Related]
34. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Heaton KM; Ju G; Grimm EA Cancer Res; 1993 Jun; 53(11):2597-602. PubMed ID: 8495422 [TBL] [Abstract][Full Text] [Related]
35. Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation. Thompson RA; Ballas ZK J Immunol; 1990 Nov; 145(10):3524-31. PubMed ID: 1700014 [TBL] [Abstract][Full Text] [Related]
36. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2. Kim KH; Lee YS; Jung IS; Park SY; Chung HY; Lee IR; Yun YS Planta Med; 1998 Mar; 64(2):110-5. PubMed ID: 9525101 [TBL] [Abstract][Full Text] [Related]
37. [Experimental study on IL-6 activity against tumor: I. Regulation of IL-2-induced LAK cells]. Lu LS Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):250-2. PubMed ID: 1396071 [TBL] [Abstract][Full Text] [Related]
38. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells. Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100 [TBL] [Abstract][Full Text] [Related]
39. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Heaton KM; Ju G; Morris DK; Delisio K; Bailon P; Grimm EA Cell Immunol; 1993 Mar; 147(1):167-79. PubMed ID: 8462109 [TBL] [Abstract][Full Text] [Related]
40. Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells. Yamauchi A; Bloom ET J Immunol; 1993 Nov; 151(10):5535-44. PubMed ID: 8228244 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]